Clinicians and laboratory professionals can rely on molar unit measurements to know the Lp(a) particle numbers.

Among older adults and adults with low ASCVD risk for whom aspirin is not recommended, use of aspirin decreased after 2019 ...

Many historically underrepresented groups, individuals on Medicaid and some without insurance at low atherosclerotic risk continue to take low-dose aspirin despite bleeding risk, in contrast to recent ...

A research team revealed that insulin-like growth factor-binding protein 6 (IGFBP6) serves as a potential therapeutic target ...

Cutaneous lupus erythematosus (CLE) is associated with an increased risk for atherosclerotic cardiovascular disease (ASCVD).

After guideline changes, aspirin use dropped off overall, even for higher-risk patients in whom it might still be considered.

A research team led by Prof. WENG Jianping from the University of Science and Technology of China (USTC) of the Chinese ...

About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform ...

Due to its unique properties, Lp(a) can vary in size and has no single, defined molecular weight. For this reason, there is a consensus in the scientific community that Lp(a) levels should be measured ...

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality globally, posing a particularly significant ...

Cardiologists reveal the unexpected symptoms of clogged arteries and underlying heart disease that you should know about. The ...

Also in the running is Silence Therapeutics, which is developing an Lp(a) siRNA candidate called SLN360 and recently reported positive phase 1 results in ASCVD patients. The category of genetic ...